Bezdekova, R. (R.)

Filtering

2017 - 201912020 - 20231

Settings

Author search.filters.isAuthorOfPublication.2e088d10-4e7e-42fe-aa2c-b715a1f03e7d

Search Results

Now showing 1 - 2 of 2
  • Thumbnail Image
    More than 2% of circulating tumor plasma cells defines plasma cell leukemia-like multiple myeloma
    (2023) Venglar, O. (Ondrej); Jelinek, T. (T.); Cedena, M.T. (María Teresa); Penka, M. (Miroslav); Jurczyszyn, A. (Artur); Polackova, P. (Petra); Bezdekova, R. (R.); Pospisilova, L. (Lenka); Sevcikova, S. (Sabina); Hajek, R. (R.); Sithara, A.A. (Anjana Anikumar); Knechtova, Z. (Zdenka); Chyra, Z. (Zuzana); Mateos, M.V. (María Victoria); Popkova, T. (Tereza); Castillo, J.J. (Jorge J.); Puig, N. (Noemí); Stork, M. (Martin); Garcés-Latre, J.J. (Juan José); Zihala, D. (David); Rihova, L. (Lucie); Hrdinka, M. (Matous); Paiva, B. (Bruno); Kapustova, V. (Veronika); Muronova, L. (Ludmila); Radocha, J. (Jakub); Simicek, M. (M.); San-Miguel, J.F. (Jesús F.); Sevcikova, T. (T.); Pour, L. (Ludek)
    PURPOSE Primary plasma cell leukemia (PCL) is the most aggressive monoclonal gammopathy. It was formerly characterized by $ 20% circulating plasma cells (CTCs) until 2021, when this threshold was decreased to $ 5%. We hypothesized that primary PCL is not a separate clinical entity, but rather that it represents ultra-high-risk multiple myeloma (MM) characterized by elevated CTC levels. METHODS We assessed the levels of CTCs by multiparameter flow cytometry in 395 patients with newly diagnosed transplant-ineligible MM to establish a cutoff for CTCs that identifies the patients with ultra-high-risk PCL-like MM. We tested the cutoff on 185 transplant-eligible patients with MM and further validated on an independent cohort of 280 transplant-ineligible patients treated in the GEM-CLARIDEX trial. The largest published real-world cohort of patients with primary PCL was used for comparison of survival. Finally, we challenged the current 5% threshold for primary PCL diagnosis. RESULTS Newly diagnosed transplant-ineligible patients with MM with 2%-20% CTCs had significantly shorter progression-free survival (3.1 v 15.6 months; P , .001) and overall survival (14.6 v 33.6 months; P 5 .023) than patients with , 2%. The 2% cutoff proved to be applicable also in transplant-eligible patients with MM and was successfully validated on an independent cohort of patients from the GEM-CLARIDEX trial. Most importantly, patients with 2%-20% CTCs had comparable dismal outcomes with primary PCL. Moreover, after revealing a low mean difference between flow cytometric and morphologic evaluation of CTCs, we showed that patients with 2%-5% CTCs have similar outcomes as those with 5%-20% CTCs. CONCLUSION Our study uncovers that $ 2% CTCs is a biomarker of hidden primary PCL and supports the assessment of CTCs by flow cytometry during the diagnostic workup of MM.
  • Thumbnail Image
    Current applications of multiparameter flow cytometry in plasma cell disorders
    (2017) Jelinek, T. (T.); Bezdekova, R. (R.); Hajek, R. (R.); Burgos, L. (Leire); Paiva, B. (Bruno); Simicek, M. (M.); Sevcikova, T. (T.); Zatopkova, M. (M.)
    Multiparameter flow cytometry (MFC) has become standard in the management of patients with plasma cell (PC) dyscrasias, and could be considered mandatory in specific areas of routine clinical practice. It plays a significant role during the differential diagnostic work-up because of its fast and conclusive readout of PC clonality, and simultaneously provides prognostic information in most monoclonal gammopathies. Recent advances in the treatment and outcomes of multiple myeloma led to the implementation of new response criteria, including minimal residual disease (MRD) status as one of the most relevant clinical endpoints with the potential to act as surrogate for survival. Recent technical progress led to the development of next-generation flow (NGF) cytometry that represents a validated, highly sensitive, cost-effective and widely available technique for standardized MRD evaluation, which also could be used for the detection of circulating tumor cells. Here we review current applications of MFC and NGF in most PC disorders including the less frequent solitary plasmocytoma, light-chain amyloidosis or Waldenström macroglobulinemia.